This month, Axial Biotherapeutics announced the appointment of leading experts in the Autism Spectrum Disorders (ASD) field to its...
Read moreWe are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made its second investment...
Read moreWe are excited to announce that Kairos Venture Partners II, L.P., our second fund, has made its first investment...
Read moreWe would like to welcome six new team members to Kairos Ventures: Danielle Walker, Chris Del Vecchio and Shahed...
Read moreKairos portfolio company, Compellon, appointed software and services veteran Carv Moore as its Chief Executive Officer to lead the...
Read moreThe NIDDK continues to fund Delpor's efforts to utilize its NANOPORâ„¢ technology in developing a matchstick-size subcutaneous implant device...
Read moreWe are happy to announce that Travis Blake has joined the Kairos team as the Principal for Physical Sciences,...
Read moreDelpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing...
Read moreThis Seed funding allows Holoclara to continue development of their immunotherapy to bring relief to millions of people suffering...
Read moreWe are pleased to announce that Neuro-Bio is the latest company to join the Kairos portfolio, following our investment...
Read more